Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy

Tamana Walia, J. Fernando Quevedo, Timothy James Hobday, Gary Croghan, Aminah Jatoi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Do colorectal cancer patients with hyperbilirubinemia and liver metastases benefit from chemotherapy? Methods/Results: This study entailed a review of 3,019 consecutive patients with colorectal cancer. Within this cohort, 20 met the study's a priori selection criteria, which included a new diagnosis of colorectal cancer, no prior therapy, and a total bilirubin of ≥3.0 mg/ dL. All 20 patients had liver metastases, and as a whole the group had a median serum bilirubin of 6.4 mg/dL (range 3.1, 28 mg/dL). Six patients received chemotherapy with an oxaliplatin-containing regimen, and four subsequently sustained a drop in their bilirubin. In one instance, a drop from 27.2 to 2.5 mg/dL occurred. These six patients lived a median of 71 days (range 23+, 283 days), but one treatment-related death occurred. In contrast, patients who received only supportive care lived a median of 28 days. Conclusion: Chemotherapy appears to provide modest benefit to newly diagnosed colorectal cancer patients with severe hyperbilirubinemia.

Original languageEnglish (US)
Pages (from-to)1363-1366
Number of pages4
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number6
StatePublished - 2008

Fingerprint

Hyperbilirubinemia
Chemotherapy
Bilirubin
Liver
Colorectal Neoplasms
oxaliplatin
cancer
Neoplasm Metastasis
Drug Therapy
death
Patient Selection
Group
Therapeutics
Serum

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Hyperbilirubinemia
  • Liver metastases
  • Oxaliplatin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

@article{ee5968e62ac24e37b60afc849df238da,
title = "Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy",
abstract = "Background: Do colorectal cancer patients with hyperbilirubinemia and liver metastases benefit from chemotherapy? Methods/Results: This study entailed a review of 3,019 consecutive patients with colorectal cancer. Within this cohort, 20 met the study's a priori selection criteria, which included a new diagnosis of colorectal cancer, no prior therapy, and a total bilirubin of ≥3.0 mg/ dL. All 20 patients had liver metastases, and as a whole the group had a median serum bilirubin of 6.4 mg/dL (range 3.1, 28 mg/dL). Six patients received chemotherapy with an oxaliplatin-containing regimen, and four subsequently sustained a drop in their bilirubin. In one instance, a drop from 27.2 to 2.5 mg/dL occurred. These six patients lived a median of 71 days (range 23+, 283 days), but one treatment-related death occurred. In contrast, patients who received only supportive care lived a median of 28 days. Conclusion: Chemotherapy appears to provide modest benefit to newly diagnosed colorectal cancer patients with severe hyperbilirubinemia.",
keywords = "Chemotherapy, Colorectal cancer, Hyperbilirubinemia, Liver metastases, Oxaliplatin",
author = "Tamana Walia and Quevedo, {J. Fernando} and Hobday, {Timothy James} and Gary Croghan and Aminah Jatoi",
year = "2008",
language = "English (US)",
volume = "4",
pages = "1363--1366",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Colorectal cancer patients with liver metastases and severe hyperbilirubinemia

T2 - A consecutive series that explores the benefits and risks of chemotherapy

AU - Walia, Tamana

AU - Quevedo, J. Fernando

AU - Hobday, Timothy James

AU - Croghan, Gary

AU - Jatoi, Aminah

PY - 2008

Y1 - 2008

N2 - Background: Do colorectal cancer patients with hyperbilirubinemia and liver metastases benefit from chemotherapy? Methods/Results: This study entailed a review of 3,019 consecutive patients with colorectal cancer. Within this cohort, 20 met the study's a priori selection criteria, which included a new diagnosis of colorectal cancer, no prior therapy, and a total bilirubin of ≥3.0 mg/ dL. All 20 patients had liver metastases, and as a whole the group had a median serum bilirubin of 6.4 mg/dL (range 3.1, 28 mg/dL). Six patients received chemotherapy with an oxaliplatin-containing regimen, and four subsequently sustained a drop in their bilirubin. In one instance, a drop from 27.2 to 2.5 mg/dL occurred. These six patients lived a median of 71 days (range 23+, 283 days), but one treatment-related death occurred. In contrast, patients who received only supportive care lived a median of 28 days. Conclusion: Chemotherapy appears to provide modest benefit to newly diagnosed colorectal cancer patients with severe hyperbilirubinemia.

AB - Background: Do colorectal cancer patients with hyperbilirubinemia and liver metastases benefit from chemotherapy? Methods/Results: This study entailed a review of 3,019 consecutive patients with colorectal cancer. Within this cohort, 20 met the study's a priori selection criteria, which included a new diagnosis of colorectal cancer, no prior therapy, and a total bilirubin of ≥3.0 mg/ dL. All 20 patients had liver metastases, and as a whole the group had a median serum bilirubin of 6.4 mg/dL (range 3.1, 28 mg/dL). Six patients received chemotherapy with an oxaliplatin-containing regimen, and four subsequently sustained a drop in their bilirubin. In one instance, a drop from 27.2 to 2.5 mg/dL occurred. These six patients lived a median of 71 days (range 23+, 283 days), but one treatment-related death occurred. In contrast, patients who received only supportive care lived a median of 28 days. Conclusion: Chemotherapy appears to provide modest benefit to newly diagnosed colorectal cancer patients with severe hyperbilirubinemia.

KW - Chemotherapy

KW - Colorectal cancer

KW - Hyperbilirubinemia

KW - Liver metastases

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=61549116926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549116926&partnerID=8YFLogxK

M3 - Article

C2 - 19337442

AN - SCOPUS:61549116926

VL - 4

SP - 1363

EP - 1366

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 6

ER -